Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | NT5E | P21589 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Methyladenosine SCHEMBL41422 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL278664 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL17124834 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL41423 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL18512844 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL18159462 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL18512845 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL6934268 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL14075776 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL13403859 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289446-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150323542-A1 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-11-12 | — | — | US | disclosed |
| US-20150283162-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD PALO ALTO, INC. | 2015-10-08 | — | — | US | disclosed |
| US-8906878-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8470801-B2 | Myocardial perfusion imaging methods and compositions | GILEAD SCIENCES, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | GILEAD SCIENCE, INC. | 2012-08-02 | — | — | US | disclosed |
| US-8183226-B2 | Myocardial perfusion imaging method | GILEAD SCIENCES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | GILEAD PALO ALTO, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7683037-B2 | A2A receptor agonist; regadenoson (CVT-3146); produces coronary vasodilation without significant peripheral vasodilation; | GILEAD PALO ALTO, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7553823-B2 | C-pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070207978-A1 | C-Pyrazole A2A receptor agonists | CV THERAPEUTICS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283162-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | LMNA 1298/4885NT5E 123/4885HIF1A 1144/4885 |
| US-20100272645-A1 | MYOCARDIAL PERFUSION IMAGING METHOD | ADORA2A, ADORA3, ADORA2B | LMNA 2390/4885NT5E 31/4885HIF1A 1247/4885 |
| US-20070207978-A1 | C-Pyrazole A2A receptor agonists | ADORA2A, ADORA3, TBXA2R | LMNA 2553/4885NT5E 381/4885HIF1A 748/4885 |
| US-20120195827-A1 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS | ADORA2A, ADORA3, ADORA1 | LMNA 1298/4885NT5E 123/4885HIF1A 1144/4885 |
| US-20150323542-A1 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS | SAMSN1, TIPARP, SPR | LMNA 2169/4885NT5E 1315/4885HIF1A 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.